COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,780 Articles (22,946 medRxiv, 8,834 bioRxiv)

Most recent first Previous |  Page 214: Articles 2131-2140  | Next

Neuroinvasive and neurovirulent potential of SARS-CoV-2 in the acute and post-acute phase of intranasally inoculated ferrets
Benavides, F. F. W., Kroeze, E. J. B. V., Leijten, L. M., Schmitz, K. S., van Run, P., Kuiken, T., de Vries, R. D., Bauer, L., van Riel, D.
10.1101/2024.09.21.614276 — Posted: 2024-09-23
Machine Learning Driven Simulations of SARS-CoV-2 Fitness Landscape
Durumeric, A. E. P., Koehler, J., Elez, K., Raich, L., Suriana, P. A., Sztain, T.
10.1101/2024.09.20.614179 — Posted: 2024-09-23
Tracing SARS-CoV-2 Clusters Across Local-scales Using Genomic Data
Lyu, L., Stott, G., Dailey, C., Subedi, S., Fujimoto, K., Penn, R., Brown, P., Sealy, R., Bahl, J.
10.1101/2024.09.18.24313896 — Posted: 2024-09-22
Wastewater surveillance overcomes socio-economic limitations of laboratory-based surveillance when monitoring disease transmission: the South African experience during the COVID-19 pandemic
Maree, G., Els, F., Naidoo, Y., Naidoo, L., Mahamuza, P., Macheke, M., Ndlovu, N., Rachida, S., Maposa, S., Taukobong, S., Iwu-Jaja, C., O'Reilly, K., Yousif, M., McCarthy, K.
10.1101/2024.09.20.24314039 — Posted: 2024-09-22
Assessing COVID-19 infection probabilities in response to alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing disease-modifying therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomide
Dornburg, A., Hassler, H. B., Townsend, J. P.
10.1101/2024.09.19.24313891 — Posted: 2024-09-22
Proteomic profiling of peripheral blood mononuclear cells reveals immune dysregulation and metabolic alterations in kidney transplant recipients with COVID-19
Leite, G. G. F., Sousa, M. B., Rodrigues, L. d. O. C. P., Brunialti, M. K. C., Medina-Pestana, J., Butler, J. M., Peters-Sengers, H., Requiao-Moura, L., Salomao, R.
10.1101/2024.09.19.24313795 — Posted: 2024-09-22
Telehealth during and beyond the COVID-19 Pandemic: Evidence from Licensed Dietitians in an Emerging Economy
Assaad, M., Chamma, N., Mateev, M., Rizk, R.
10.1101/2024.09.19.24314030 — Posted: 2024-09-22
COVID-19 Vaccine effectiveness among Healthcare Workers during the Omicron Period in the country of Georgia, January - June 2022
Ward, C. L., Rojas Castro, M. Y., Chakhunashvili, G., Chitadze, N., Finci, I., Pebody, R., Kissling, E., Katz, M. A., Sanodze, L.
10.1101/2024.09.19.24314033 — Posted: 2024-09-22
Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant
Singh, V., Choudhary, S., Bhutkar, M., Nehul, S., Ali, S., Singla, J., Kumar, P., Tomar, S.
10.1101/2024.09.19.613860 — Posted: 2024-09-20
Chain Termination Effects of Chemically Modified Nucleoside Analogs on SARS-CoV-2 RNA Polymerase
Yang, L., Xu, X., Liang, Z., Zhang, B., Tse, K., Cheung, P. P.-H.
10.1101/2024.09.20.614085 — Posted: 2024-09-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).